Therapy of ulcus cruris of venous and mixed venous arterial origin with autologous, adult, native progenitor cells from subcutaneous adipose tissue: a prospective clinical pilot study

Konstantinow, Alexander; Arnold, Amber; Djabali, K.; Kempf, W.; Gutermuth, Jan; Fischer, Tatjana; Biedermann, Tilo

doi:10.1111/jdv.14489

Cited by 34 publications

(25 citation statements)

References 94 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the last years, freshly isolated, uncultured, autologous adipose-derived regenerative cells (UA-ADRCs) have become highly attractive for the practice of regenerative cell therapy (e.g., [6][7][8][9][10]) (note that freshly isolated, uncultured, adipose-derived regenerative cells were also named "stromal vascular fraction" (SVF) in many publications; e.g., [11][12][13]). This is due to the fact that UA-ADRCs have several advantages over other types of cells used in and/or under investigation for regenerative cell therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Third, adipose tissue typically has a significantly higher stem cell density than bone marrow (5 to 10% vs. 0.1%), and harvesting adipose tissue can be less invasive than harvesting bone marrow [23,24]. Fourth, unlike the use of adipose derived stem cells (ASCs) which are culture-expanded from the SVF [25][26][27], the use of UA-ADRCs allows immediate usage at point of care [8][9][10]. This is combined with low safety concerns as no culturing or modification are applied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Winnier¹,

Valenzuela²,

Peters-Hall³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Freshly isolated, uncultured, autologous adipose derived regenerative cells (ADRCs) have emerged as a promising tool for regenerative cell therapy. The Transpose RT system (InGeneron, Inc., Houston, TX, USA) is a system for isolating ADRCs from adipose tissue, commercially available in Europe as a CE-marked medical device and under clinical evaluation in the United States. This system makes use of the proprietary, enzymatic Matrase Reagent for isolating cells. The present study addressed the question whether the use of Matrase Reagent influences cell yield, cell viability, live cell yield, biological characteristics, physiological functions or structural properties of the ADRCs in final cell suspension. Identical samples of subcutaneous adipose tissue from 12 subjects undergoing elective lipoplasty were processed either with or without the use of Matrase Reagent. Then, characteristics of the ADRCs in the respective final cell suspensions were evaluated. Compared to non-enzymatic isolation, enzymatic isolation resulted in approximately twelve times higher mean cell yield (i.e., numbers of viable cells/ml lipoaspirate) and approximately 16 times more colony forming units. Despite these differences, cells isolated from lipoaspirate both with and without the use of Matrase Reagent were independently able to differentiate into cells of all three germ layers. This indicates that biological characteristics, physiological functions or structural properties relevant for the intended use were not altered or induced using Matrase Reagent. A comprehensive literature review demonstrated that isolation of ADRCs from lipoaspirate using the Transpose RT system and the Matrase Reagent results in the highest viable cell yield among published data regarding isolation of ADRCs from lipoaspirate.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Winnier¹,

Valenzuela²,

Peters-Hall³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Over the last years, fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) have become highly attractive for the practice of regenerative cell therapy (e.g., [6][7][8][9][10]) (note that fresh, uncultured, unmodified adipose-derived regenerative cells were also named "stromal vascular fraction" (SVF) in many publications; e.g., [11][12][13]). This is due to the fact that UA-ADRCs have several advantages over other types of cells used in and/or under investigation for regenerative cell therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Third, adipose tissue typically has a significantly higher stem cell density than bone marrow (5 to 10% vs. 0.1%), and harvesting adipose tissue can be less invasive than harvesting bone marrow [23,24]. Fourth, unlike the use of adipose derived stem cells (ASCs) which are culture-expanded from the SVF (e.g., [25][26][27]), the use of UA-ADRCs allows immediate usage at point of care (e.g., [8][9][10]). This is combined with low safety concerns as no culturing or modification are applied.…”

Section: Introductionmentioning

confidence: 99%

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Valenzuela

Alt

Winnier

et al. 2018

Preprint

View full text Add to dashboard Cite

Background: Freshly isolated, unmodified autologous adipose derived regenerative cells (ADRCs) have emerged as a promising tool for regenerative cell therapy. The Transpose RT system (InGeneron, Inc., Houston, TX, USA) is a system for isolating ADRCs from adipose tissue, commercially available in Europe as a CE-marked medical device and under clinical evaluation in the United States. This system makes use of the proprietary, enzymatic Matrase Reagent for isolating cells. The present study addressed the question whether the use of Matrase Reagent influences cell yield, cell recovery, cell viability, biological characteristics, physiological functions or structural properties of the ADRCs in final cell suspension. Methods: Identical samples of subcutaneous adipose tissue from 12 subjects undergoing elective lipoplasty were processed either with or without the use of Matrase Reagent. Then, characteristics of the ADRCs in the respective final cell suspensions were evaluated. Results: Compared to non-enzymatic isolation, enzymatic isolation resulted in approximately twelve times higher mean cell yield (i.e., numbers of viable cells/ml lipoaspirate) and approximately 16 times more colony forming units (CFUs). Despite these differences, cells isolated from lipoaspirate both with and without the use of Matrase Reagent were independently able to differentiate into cells of all three germ layers. Discussion: The data of this study indicate that biological characteristics, physiological functions or structural properties relevant for the intended use were not altered or induced using Matrase Reagent. A comprehensive literature review demonstrated that isolation of ADRCs from lipoaspirate using the Transpose RT system and the Matrase Reagent results in the highest viable cell yield among all published data regarding isolation of ADRCs from lipoaspirate. ABSTRACTBackground: Freshly isolated, unmodified autologous adipose derived regenerative cells (ADRCs) have emerged as a promising tool for regenerative cell therapy. The Transpose RT system (InGeneron, Inc., Houston, TX, USA) is a system for isolating ADRCs from adipose tissue, commercially available in Europe as a CE-marked medical device and under clinical evaluation in the United States. This system makes use of the proprietary, enzymatic Matrase Reagent for isolating cells. The present study addressed the question whether the use of Matrase Reagent influences cell yield, cell recovery, cell viability, biological characteristics, physiological functions or structural properties of the ADRCs in final cell suspension. Methods: Identical samples of subcutaneous adipose tissue from 12 subjects undergoing elective lipoplasty were processed either with or without the use of Matrase Reagent. Then, characteristics of the ADRCs in the respective final cell suspensions were evaluated. Results: Compared to non-enzymatic isolation, enzymatic isolation resulted in approximately twelve times higher mean cell yield (i.e., numbers of viable cells/ml lipoaspirate) and approximately 16 tim...

show abstract

“…A zsírszövetből kinyert őssejtekkel történő vénás lábszárfekély gyógyításnak meglepően korlátozott az irodalma, de egy friss német vizsgálat alapján fél éven belül az összes tisztán vénás eredetű aktív lábszárfekélyt be lehetett gyógyítani az autológ, zsírszövetből szeparált őssejtek egyszeri alkalmazásával a fekélyalapba fecskendezve (23).…”

Section: őSsejt Kezelésunclassified

Novel aspects of lymphedema-, and venous leg ulcer-related pathomechanism and therapy

Szolnoky¹,

Erős²,

Degovics³

et al. 2019

BVSZ

View full text Add to dashboard Cite

Ez az áttekintés a krónikus sebek és a nyiroködéma patomechanizmusának és kezelésének legfrissebb ismereteivel foglalkozik, kiemelve azt is, hogy a nyirokkeringési zavar mindkét esetben jelentős szereppel bír a két betegség kialakulásában. Habár továbbra is a kompresszió terápia képviseli a legalapvetőbb konzervatív kezelési módszert mind a vénás lábszárfekély, mind pedig a nyiroködéma esetén, az elmúlt időszakban néhány olyan új eredmény látott napvilágot, amelyek reménnyel kecsegtetnek a terápia eredményességének javításában.

show abstract

Therapy of ulcus cruris of venous and mixed venous arterial origin with autologous, adult, native progenitor cells from subcutaneous adipose tissue: a prospective clinical pilot study

Cited by 34 publications

References 94 publications

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Isolation of adipose tissue derived regenerative cells from human subcutaneous tissue with or without the use of an enzymatic reagent

Novel aspects of lymphedema-, and venous leg ulcer-related pathomechanism and therapy

Contact Info

Product

Resources

About